Paper3422166
The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.
Broze GJ and 5 others. Blood, 1988. Cited by 485 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Papers, record 3422166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3422166
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anticoagulants | Major topic |
| Blood Coagulation | Major topic |
| Factor VII | Major topic |
| Lipoproteins | Major topic |
| Neoplasm Proteins | Major topic |
| Serine Proteinase Inhibitors | Major topic |
| Calcium | |
| Factor Xa | |
| In Vitro Techniques | |
| Peptide Fragments | |
| Protein Binding | |
| Structure-Activity Relationship | |
| Thrombin | |
| Thromboplastin |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| HL14147 | NHLBI NIH HHS | United States | P17HL014147 | PubMed and NIH | NIH RePORTER |
| HL34462 | NHLBI NIH HHS | United States | R01HL034462 | PubMed and NIH | NIH RePORTER |
| P50HL014147 | NIH | NIH RePORTER |
Cited by93
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 485 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,405,179 | Mechanism and kinetics study of MG1113, an anti-tissue factor pathway inhibitor antibody promoting hemostasis in hemophilia. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42405179 | PubMed |
| 42,237,715 | An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3. | Haemophilia | 2026 | https://conductscience.org/library/papers/42237715 | PubMed |
| 41,962,001 | TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short. | Blood Adv | 2026 | https://conductscience.org/library/papers/41962001 | PubMed |
| 40,980,255 | Evaluation of a new commercial assay for the measurement of tissue factor activity of extracellular vesicles isolated from human plasma. | Res Pract Thromb Haemost | 2025 | https://conductscience.org/library/papers/40980255 | PubMed |
| 39,624,584 | Extracellular vesicle tissue factor and tissue factor pathway inhibitor are independent discriminators of sepsis-induced coagulopathy. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/39624584 | PubMed |
| 36,813,269 | Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death. | J Matern Fetal Neonatal Med | 2023 | https://conductscience.org/library/papers/36813269 | PubMed |
| 36,611,442 | Haemostasis and Inflammatory Parameters as Potential Diagnostic Biomarkers for VTE in Trauma-Immobilized Patients. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/36611442 | PubMed |
| 34,876,522 | Intersection of regulatory pathways controlling hemostasis and hemochorial placentation. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34876522 | PubMed |
| 34,163,136 | Recent Advances in the Treatment of Hemophilia: A Review. | Biologics | 2021 | https://conductscience.org/library/papers/34163136 | PubMed |
| 33,034,200 | Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. | Clin Appl Thromb Hemost | 2020 | https://conductscience.org/library/papers/33034200 | PubMed |
| 32,141,012 | Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways. | Inflammopharmacology | 2020 | https://conductscience.org/library/papers/32141012 | PubMed |
| 32,099,678 | Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. | J Lipids | 2020 | https://conductscience.org/library/papers/32099678 | PubMed |
| 32,029,851 | Production and control of coagulation proteins for factor X activation in human endothelial cells and fibroblasts. | Sci Rep | 2020 | https://conductscience.org/library/papers/32029851 | PubMed |
| 30,850,987 | Revisiting the Pharmacology of Unfractionated Heparin. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/30850987 | PubMed |
| 30,302,740 | Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. | Int J Hematol | 2020 | https://conductscience.org/library/papers/30302740 | PubMed |
| 30,194,803 | Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. | J Thromb Haemost | 2018 | https://conductscience.org/library/papers/30194803 | PubMed |
| 30,039,454 | First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. | J Thromb Thrombolysis | 2018 | https://conductscience.org/library/papers/30039454 | PubMed |
| 29,845,491 | Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. | Drugs | 2018 | https://conductscience.org/library/papers/29845491 | PubMed |
| 29,050,502 | First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. | Clin Appl Thromb Hemost | 2018 | https://conductscience.org/library/papers/29050502 | PubMed |
| 28,521,572 | Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes. | J Matern Fetal Neonatal Med | 2018 | https://conductscience.org/library/papers/28521572 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| F10 | 2,159 | PubTator's text mining | https://conductscience.org/library/genes/2159 | NCBI Gene |
| F3 | 2,152 | PubTator's text mining | https://conductscience.org/library/genes/2152 | NCBI Gene |
| F7 | 2,155 | PubTator's text mining | https://conductscience.org/library/genes/2155 | NCBI Gene |
| F9 | 2,158 | PubTator's text mining | https://conductscience.org/library/genes/2158 | NCBI Gene |
| PCID2 | 55,795 | PubTator's text mining | https://conductscience.org/library/genes/55795 | NCBI Gene |
| TFPI | 7,035 | PubTator's text mining | https://conductscience.org/library/genes/7035 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3422166
GET https://conductscience.org/api/papers/v1/3422166/cited_by?page=2